Pharming has bought a late-stage pipeline drug aimed at a rare disease of the immune system from Novartis for $20 million up front, plus other payments further down the line.
Novartis has announced that its heart failure drug Entresto has failed in a trial that the company hoped would extend its use to a new group of patients with preserved ejection fraction.
The FDA has accelerated its review of Novartis’ sickle cell drug crizanlizumab after the company filed phase 2 results showing its effectiveness as a treatment for life threatening and pain